Vismita Gupta-Smith Hello and welcome to Science in 5. I'm Vismita Gupta-Smith and this is WHO's conversations in science. We're going to continue our conversation on COVID-19 vaccines and explaining the science and evidence behind it is WHO's Chief Scientist Dr. Soumya Swaminathan. Welcome, Soumya. https://youtu.be/ihi55JzTCqU https://youtu.be/ihi55JzTCqU
USP is hosting a Global Seminar Series, Ensuring Quality Hand Sanitizer Production During COVID-19, to help ensure quality alcohol-based hand sanitizer production and support the safe use of alcohol-based hand sanitizer, February 25th, 2021.
For more information go to: USP Global Seminar Series: Ensuring Quality Hand Sanitizer Production During COVID-19 for Manufacturers and Healthcare Providers in Latin America – Event Summary | Online Registration by Cvent
The United States Pharmacopeia published “COVID-19 Vaccine Handling Toolkit: Operational Considerations for Healthcare Practitioners”, available at https://www.usp.org/covid-19/vaccine-handling-toolkit.
PAHO published Questions and answers (Q&A) on regulatory matters related to the introduction and pharmacovigilance of vaccines against COVID-19, available at PAHOIMSHSSMTCOVID-19210001_eng.pdf
On Monday (30/11), Anvisa was formally informed of the successful completion of the Agency’s process of adhering to the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Anvisa will become the 54th member of the international initiative in pharmaceutical inspection, and will have the international recognition of the excellence of inspections in Good Manufacturing Practices (GMP) of medicines and pharmaceutical inputs for human use.
This document, which is an update of the guidance published on 5 June 2020, includes new scientific evidence relevant to the use of masks for reducing the spread of SARS-CoV-2, the virus that causes COVID-19, and practical considerations. It contains updated evidence and guidance on the following:
• mask management;
• SARS-CoV-2 transmission;
• masking in health facilities in areas with community, cluster and sporadic transmission;
• mask use by the public in areas with community and cluster transmission;
• alternatives to non-medical masks for the public;
• exhalation valves on respirators and non-medical masks;
• mask use during vigorous intensity physical activity;
• essential parameters to be considered when manufacturing non-medical masks (Annex).
Mask use in the context of COVID-19: interim guidance, 1 December 2020 (who.int)
Date:
December 2, 2020
Time:
12:15 PM – 1:15 PM ET
Health Canada and COVID-19 health product industry
26/11/2020 16h53
Empresa Pfizer protocolou documentos relativos às fases não-clínicas e clínicas I e II. A submissão contínua ainda não é o pedido de registro.
26/11/2020 13h50
Na terça-feira (1º/12), às 15h, a Agência irá realizar um seminário virtual sobre as ações de farmacovigilância no enfrentamento da Covid-19. Participe!
25/11/2020 09h48
Problema pode ser agravado e acelerado por conta do uso indevido de antibióticos.
20/11/2020 09h25
Brasil irá inspecionar as plantas de produção específicas das vacinas contra Covid-19 na China.
https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus
Cofepris actions on Covid-19 (In Spanish)
https://www.gob.mx/cofepris/acciones-y-programas/acciones-sobre-covid-19?state=published
